Elanco Animal Health Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022; comparisons are against Q1 2021. Elanco is a global animal-health company serving pet and farm-animal markets. Results are unaudited, and the company cautions that pet-health seasonality makes interim results an uncertain guide to full-year performance.
Financial performance and position
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Revenue | $1,225 million | $1,242 million |
| Gross profit / gross margin | $716 million / 58.4% | $673 million / 54.2% |
| Income (loss) before taxes | $71 million | $(80) million |
| Income tax expense (benefit) | $23 million | $(19) million |
| Net income (loss) | $48 million | $(61) million |
| Diluted earnings (loss) per share | $0.10 | $(0.12) |
| Operating cash flow | $(62) million | $22 million |
| Cash and cash equivalents, March 31 | $342 million | $638 million at Dec. 31, 2021 |
| Total debt, March 31 | $6,134 million | $6,319 million at Dec. 31, 2021 |
Gross profit and gross margin are calculated from reported revenue less cost of sales. Q1 2021 included $62 million of acquired-inventory fair-value step-up amortization; excluding that item, the filing says cost of sales would have been approximately 41% of revenue, versus 42% in Q1 2022. Cash used in investing and financing activities was $29 million and $200 million, respectively. Cash declined by $296 million during the quarter. Current assets were $3,194 million and current liabilities $1,307 million at March 31.
Revenue comprised Pet Health of $639 million (down 1%), Farm Animal of $569 million (down 2%) and contract manufacturing of $17 million (down 11%). Reported revenue fell 1%; excluding foreign exchange, revenue grew 2%. Price contributed 2%, foreign exchange reduced revenue 3%, and volume was essentially flat overall.
Changes versus the prior comparable period
- Net income improved by $109 million, from a $61 million loss to $48 million of income; pretax results improved by $151 million.
- Cost of sales fell 11%, and its reported share of revenue declined from 46% to 42%. The comparison benefits from the absence of the prior-year $62 million inventory fair-value step-up and from manufacturing productivity improvements; inflation, freight and conversion costs partly offset those benefits.
- Marketing, selling and administrative expense decreased 8% to $320 million; R&D expense decreased 9% to $81 million. Management cited cost discipline and savings from restructuring.
- Asset impairment, restructuring and other special charges declined to $46 million from $108 million. Q1 2022 included a $28 million write-down on the Speke site sale and $24 million of transaction and integration costs; restructuring credits were $7 million.
- Interest expense decreased 15% to $52 million, primarily due to refinancing at lower rates. Other expense was $9 million, mainly from foreign-exchange losses and investment fair-value adjustments.
- Operating cash flow worsened by $84 million, primarily because of changes in operating assets and liabilities, including receivables, payables and other liabilities.
Outlook, risks, contingencies and unusual items
- Outlook: The filing provides no numerical earnings or revenue guidance. Management said available liquidity and expected cash flows should fund planned and existing needs and support covenant compliance, but noted that economic volatility could affect liquidity and access to financing. It expects continued integration costs for Bayer Animal Health and KindredBio, partly offset by anticipated synergies.
- Debt and subsequent financing: Elanco was in compliance with revolving-credit covenants at March 31. In April, it retired $406 million of 2023 senior notes using a revolving-credit draw, expecting to record an approximately $17 million debt-extinguishment loss in Q2. It also arranged a $250 million incremental term facility, whose proceeds repaid part of the revolver balance.
- Interest-rate swaps: In April, Elanco replaced existing swaps with new agreements covering the same notional amounts and tenors, receiving $132 million in cash. It expects to reclassify approximately $47 million of prior unrealized gains into interest expense over the next 12 months.
- Business and macroeconomic risks: Supply-chain disruption, raw-material shortages, freight and input-cost inflation, labor constraints, foreign exchange, COVID-19 effects, generic competition and the Russia-Ukraine conflict could affect costs, supply, demand and earnings. Russia and Ukraine represented approximately 1% of Q1 revenue; Russian assets were less than 1% of total assets. The company limited Russian business to essential products and said it did not source materials from Russia.
- Legal and regulatory matters: Elanco disclosed shareholder litigation concerning prior disclosures and distribution practices, Seresto-collar class actions and an SEC subpoena concerning channel inventory and sales practices before mid-2020. The EPA was considering a petition seeking action on Seresto’s registration; Elanco said it supports the product’s safety and is cooperating with authorities. No material litigation liabilities were accrued because no significant claim was considered both probable and estimable.
- Other items: Elanco completed the Speke manufacturing-site sale in February and recorded the related $28 million write-down. In April, it agreed to transfer its microbiome R&D platform assets to BiomEdit, retaining a minority stake; it expected a disposal gain in Q2, with accounting not yet complete. A future Indianapolis headquarters lease is expected to begin in 2024 and carries estimated minimum payments of approximately $310 million over 25 years.
- Controls: Management concluded disclosure controls were effective as of March 31, 2022; it reported no material change in internal control over financial reporting during the quarter.
Key facts investors should verify
- Whether revenue growth excluding foreign exchange translates into sustained reported growth, particularly as pet-health sales are seasonal and older parasiticide products face declines.
- Whether productivity gains and pricing can offset inflation, freight costs, generic competition and supply constraints—and how comparable gross margins are after the prior-year inventory step-up.
- Whether operating cash flow recovers after the working-capital outflow, and how cash, debt and revolving-credit usage evolve following the April transactions.
- The amounts and timing of integration and restructuring costs, anticipated synergies, and any further adjustments to the Speke or BiomEdit transactions.
- Developments in the Seresto litigation and regulatory review, shareholder lawsuits, and the SEC inquiry; the filing does not quantify potential exposure.